Evidence map›Paper›PMID 42292362›Full record

ReviewFrontiers in immunology2026

Teleology of immune system response to sepsis - failure due to dysregulation or adaptive response that sometimes fails?

Krzysztof Laudanski

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Krzysztof LaudanskiDepartment of Anesthesiology and Perioperative Care, Mayo Clinic, Rochester, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Critical-grade insults (CGIs), such as sepsis, pose extreme challenges to host homeostasis. Although unfavorable immune responses in these conditions are commonly described as dysregulated, such perturbations are often defined retrospectively based on clinical outcomes rather than on the underlying immune processes. Here, I propose that, particularly in its early phase, the immune system response to sepsis reflects a high-stakes host response aimed at rapid control of the insult, albeit one that carries substantial risk to the host. If the inciting challenge is effectively contained, the immune response may resolve and transition toward tissue repair and recovery. Conversely, failure to control the insult may result in host death. In this context, the early immune response can be conceptualized within a "win versus loss" framework, where win is described as the ability to control inciting insult, while loss is host demise. Consequently, the term "dysregulation" may not fully capture the probabilistic feature of the initial response. Rather than representing a simple failure of control, this response may reflect an aggressive but potentially hazardous strategy that, in some cases, proves unsuccessful. Timely medical interventions, including appropriate antibiotic therapy, source control, or immunological endotype-based strategies, can modify CGI immunological trajectory by limiting insult burden and reducing the duration and intensity of the host response, thereby improving the likelihood of survival. Nevertheless, sustained or excessive early immune activation may disrupt regulatory networks, resulting in inevitable demise in some individuals, while others will exhibit an emergence of maladaptive allostatic states that can impair full recovery.

Indexed as

Adaptive ImmunityImmune SystemSepsisAnimalsHomeostasisHumansallostasisCritical grade insulthomeostasisimmune responselong-term outcomesseptic shockteleology

Identifiers

PMID42292362
PMCPMC13253370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.